Expression Genetics, Inc.
Records under this name other than patents Expression Genetics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Expression Genetics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,571 | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,468,687 | Immuno gene therapy for treatment of cancer and hyperproliferative diseases Formerly held Term ended Term ended Feb 7, 2026 · From the USPTO record | Term ended | Term ended Feb 7, 2026 | From the USPTO record |
| US 8,623,837 | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases Formerly held Term ended Term ended Dec 24, 2025 · From the USPTO record | Term ended | Term ended Dec 24, 2025 | From the USPTO record |
| US 8,445,017 | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof Formerly held Term ended Term ended Jan 24, 2025 · From the USPTO record | Term ended | Term ended Jan 24, 2025 | From the USPTO record |
| US 7,374,930 | GLP-1 gene delivery for the treatment of type 2 diabetes Formerly held Term ended Term ended Jul 25, 2024 · From the USPTO record | Term ended | Term ended Jul 25, 2024 | From the USPTO record |
| US 8,057,821 | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof Formerly held Lapsed on the fee record Ended Nov 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2023 | From the USPTO record |
| US 6,586,524 | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier Formerly held Term ended Term ended Jul 19, 2021 · From the USPTO record | Term ended | Term ended Jul 19, 2021 | From the USPTO record |
| US 6,652,886 | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents Formerly held Term ended Term ended Feb 16, 2021 · From the USPTO record | Term ended | Term ended Feb 16, 2021 | From the USPTO record |
| US 6,696,038 | Cationic lipopolymer as biocompatible gene delivery agent Formerly held Term ended Term ended Sep 14, 2020 · From the USPTO record | Term ended | Term ended Sep 14, 2020 | From the USPTO record |
| US 6,177,274 | Hepatocyte targeting polyethylene glyco-grafted poly-L-lysine polymeric gene carrier Formerly held Term ended Term ended May 20, 2019 · From the USPTO record | Term ended | Term ended May 20, 2019 | From the USPTO record |